BeyondSpring Inc. (NASDAQ: BYSI) reported a net loss of $14.2 million for the fourth quarter of 2025, translating to a loss of $0.05 per share. The company did not record any product sales revenue, reflecting its status as a clinical‑stage biopharmaceutical.
Cash on hand stood at $12.6 million as of December 31 2025, while operating cash flow was –$16.4 million for the year. The current burn rate implies a runway of roughly nine months, underscoring the urgency of securing additional capital or achieving a regulatory milestone to sustain operations.
BeyondSpring is in the process of selling a portion of its Series A‑1 preferred shares in SEED Therapeutics. The divestiture will reduce the company’s equity stake in SEED, freeing capital that can be deployed toward its own clinical programs while maintaining a strategic partnership with the TPD‑focused company.
The company’s lead candidate, Plinabulin, has received Breakthrough Therapy Designation from the FDA and a similar designation from China’s NMPA for chemotherapy‑induced neutropenia. A new drug application has been submitted for the combination of Plinabulin with G‑CSF, and the company has secured upfront and milestone payments from a partnership with Jiangsu Hengrui Pharmaceuticals for Greater China rights.
CEO Dr. Lan Huang said, “2025 was a year of important clinical and operational progress for BeyondSpring and SEED Therapeutics.” He added, “With a solid scientific and clinical foundation and clear regulatory pathways, we believe BeyondSpring and SEED are well positioned for the next stage of development.” He also noted the company’s focus on advancing the DUBLIN‑4 confirmatory trial for Plinabulin in non‑squamous EGFR wild‑type NSCLC post‑immune checkpoint inhibitors and supporting SEED’s Phase 1a program for ST‑01156 in solid tumors.
The earnings release highlights the company’s continued cash burn and the need for future financing or a regulatory breakthrough. While the loss per share aligns with expectations for a pre‑revenue, clinical‑stage firm, the constrained runway and ongoing divestiture underscore the importance of achieving the next milestone to avoid liquidity pressure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.